



## Clinical trial results:

### A Phase 2 Pilot, Multicenter, Single Arm Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of GSK1070806 plus Standard of Care for the Prevention of Delayed Graft Function in Adult Subjects After Renal Transplantation

#### Summary

|                          |                |
|--------------------------|----------------|
| EudraCT number           | 2015-002812-33 |
| Trial protocol           | GB ES          |
| Global end of trial date | 06 March 2018  |

#### Results information

|                                |               |
|--------------------------------|---------------|
| Result version number          | v4 (current)  |
| This version publication date  | 03 July 2019  |
| First version publication date | 15 April 2018 |
| Version creation reason        |               |

#### Trial information

##### Trial identification

|                       |        |
|-----------------------|--------|
| Sponsor protocol code | 204824 |
|-----------------------|--------|

##### Additional study identifiers

|                                    |   |
|------------------------------------|---|
| ISRCTN number                      | - |
| ClinicalTrials.gov id (NCT number) | - |
| WHO universal trial number (UTN)   | - |

Notes:

#### Sponsors

|                              |                                                            |
|------------------------------|------------------------------------------------------------|
| Sponsor organisation name    | GlaxoSmithKline                                            |
| Sponsor organisation address | 980 Great West Road, Brentford, Middlesex, United Kingdom, |
| Public contact               | GSK Response Center, GlaxoSmithKline, 1 866-435-7343,      |
| Scientific contact           | GSK Response Center, GlaxoSmithKline, 1 866-435-7343,      |

Notes:

#### Paediatric regulatory details

|                                                                      |    |
|----------------------------------------------------------------------|----|
| Is trial part of an agreed paediatric investigation plan (PIP)       | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

## Results analysis stage

|                                                      |                |
|------------------------------------------------------|----------------|
| Analysis stage                                       | Final          |
| Date of interim/final analysis                       | 16 August 2018 |
| Is this the analysis of the primary completion data? | No             |
| Global end of trial reached?                         | Yes            |
| Global end of trial date                             | 06 March 2018  |
| Was the trial ended prematurely?                     | Yes            |

Notes:

## General information about the trial

Main objective of the trial:

To assess the frequency of delayed graft function (DGF) in donation after circulatory death (DCD) renal transplant recipients treated with GSK1070806

Protection of trial subjects:

This study uses standard of care (SoC) aligning study tasks with SoC tasks and visit schedule to mitigate participant study-burden. Additionally, participants are required to use additional anti-infective protocols due to the potential of GSK1070806 to increase immunosuppression.

Background therapy: -

Evidence for comparator: -

|                                                           |                |
|-----------------------------------------------------------|----------------|
| Actual start date of recruitment                          | 27 August 2016 |
| Long term follow-up planned                               | No             |
| Independent data monitoring committee (IDMC) involvement? | No             |

Notes:

## Population of trial subjects

### Subjects enrolled per country

|                                      |                   |
|--------------------------------------|-------------------|
| Country: Number of subjects enrolled | Spain: 1          |
| Country: Number of subjects enrolled | United Kingdom: 6 |
| Worldwide total number of subjects   | 7                 |
| EEA total number of subjects         | 7                 |

Notes:

### Subjects enrolled per age group

|                                           |   |
|-------------------------------------------|---|
| In utero                                  | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days)                      | 0 |
| Infants and toddlers (28 days-23 months)  | 0 |
| Children (2-11 years)                     | 0 |
| Adolescents (12-17 years)                 | 0 |
| Adults (18-64 years)                      | 5 |
| From 65 to 84 years                       | 2 |
| 85 years and over                         | 0 |

## Subject disposition

### Recruitment

Recruitment details:

This was a single arm study to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of GSK1070806 plus standard of care (SOC) for the prevention of delayed graft function in adult participants after renal transplantation.

### Pre-assignment

Screening details:

A total of 10 participants were screened for the study, and 7 of them received study treatment. The study enrolled participants in 4 centers across 2 countries (Spain and United Kingdom).

### Period 1

|                              |                                |
|------------------------------|--------------------------------|
| Period 1 title               | Overall Study (overall period) |
| Is this the baseline period? | Yes                            |
| Allocation method            | Not applicable                 |
| Blinding used                | Not blinded                    |

### Arms

|                  |                       |
|------------------|-----------------------|
| <b>Arm title</b> | GSK1070806 3 mg/kg IV |
|------------------|-----------------------|

Arm description:

Participants received a single dose of 3 milligram per kilogram (mg/kg) intravenous (IV) infusion of GSK1070806 administered prior to kidney allograft reperfusion. Participants also received a combination immunosuppression comprised of basiliximab; mycophenolate mofetil (MMF) or aziothioprine; tacrolimus; and corticosteroids based on the clinical judgment of the investigator.

|                                        |                 |
|----------------------------------------|-----------------|
| Arm type                               | Experimental    |
| Investigational medicinal product name | GSK1070806      |
| Investigational medicinal product code |                 |
| Other name                             |                 |
| Pharmaceutical forms                   | Infusion        |
| Routes of administration               | Intravenous use |

Dosage and administration details:

Participants received a single dose of 3 milligram per kilogram (mg/kg) intravenous (IV) infusion of GSK1070806 administered prior to kidney allograft reperfusion.

|                                       |                       |
|---------------------------------------|-----------------------|
| <b>Number of subjects in period 1</b> | GSK1070806 3 mg/kg IV |
| Started                               | 7                     |
| Completed                             | 6                     |
| Not completed                         | 1                     |
| Lost to follow-up                     | 1                     |

## Baseline characteristics

### Reporting groups

|                       |                       |
|-----------------------|-----------------------|
| Reporting group title | GSK1070806 3 mg/kg IV |
|-----------------------|-----------------------|

Reporting group description:

Participants received a single dose of 3 milligram per kilogram (mg/kg) intravenous (IV) infusion of GSK1070806 administered prior to kidney allograft reperfusion. Participants also received a combination immunosuppression comprised of basiliximab; mycophenolate mofetil (MMF) or aziothioprine; tacrolimus; and corticosteroids based on the clinical judgment of the investigator.

| Reporting group values                                                  | GSK1070806 3 mg/kg IV | Total |  |
|-------------------------------------------------------------------------|-----------------------|-------|--|
| Number of subjects                                                      | 7                     | 7     |  |
| Age categorical<br>Units: Subjects                                      |                       |       |  |
| All Participants                                                        | 7                     | 7     |  |
| Age continuous<br>Units: years<br>arithmetic mean<br>standard deviation | 58.7<br>± 13.46       | -     |  |
| Gender categorical<br>Units: Subjects                                   |                       |       |  |
| Female                                                                  | 0                     | 0     |  |
| Male                                                                    | 7                     | 7     |  |
| Race/Ethnicity, Customized<br>Units: Subjects                           |                       |       |  |
| White                                                                   | 7                     | 7     |  |

## End points

### End points reporting groups

|                                                                                                                                                                                                                                                                                                                                                                                                                            |                       |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| Reporting group title                                                                                                                                                                                                                                                                                                                                                                                                      | GSK1070806 3 mg/kg IV |
| Reporting group description:<br>Participants received a single dose of 3 milligram per kilogram (mg/kg) intravenous (IV) infusion of GSK1070806 administered prior to kidney allograft reperfusion. Participants also received a combination immunosuppression comprised of basiliximab; mycophenolate mofetil (MMF) or aziothioprine; tacrolimus; and corticosteroids based on the clinical judgment of the investigator. |                       |

### Primary: Number of participants requiring dialysis during the first 7 days post transplant

|                 |                                                                                                  |
|-----------------|--------------------------------------------------------------------------------------------------|
| End point title | Number of participants requiring dialysis during the first 7 days post transplant <sup>[1]</sup> |
|-----------------|--------------------------------------------------------------------------------------------------|

#### End point description:

The requirement of dialysis (except as needed for hyperkalemia during the first 24 hours [hrs]) were used to assess the frequency of delayed graft function (DGF) in donation after circulatory death (DCD) renal transplant recipients treated with GSK1070806. The 'Analysis Population' (AP) is defined as participants in the 'All Subjects' Population who have been declared to have DGF or have reached 7 days. Statistical analysis was carried out using Bayesian methodology. The proportion of participants with DGF was 0.57, highest Posterior Density (HPD) 95% Credible interval (CI) (0.25,0.90). The posterior probability for the proportion of participants with DGF <30% was 0.07 (HPD 95% CI [0.00,1.00]). The posterior probability for the proportion of participants with DGF <50% was 0.34 (HPD 95% CI [0.00,1.00]).

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

#### End point timeframe:

Up to Day 7

#### Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical details are presented in outcome measure description for this single arm endpoint.

|                             |                       |  |  |  |
|-----------------------------|-----------------------|--|--|--|
| <b>End point values</b>     | GSK1070806 3 mg/kg IV |  |  |  |
| Subject group type          | Reporting group       |  |  |  |
| Number of subjects analysed | 7 <sup>[2]</sup>      |  |  |  |
| Units: Participants         |                       |  |  |  |
| Participants                | 4                     |  |  |  |

#### Notes:

[2] - AP Population

### Statistical analyses

No statistical analyses for this end point

### Secondary: Serum creatinine at Baseline and Change from Baseline over time post transplant

|                 |                                                                                 |
|-----------------|---------------------------------------------------------------------------------|
| End point title | Serum creatinine at Baseline and Change from Baseline over time post transplant |
|-----------------|---------------------------------------------------------------------------------|

#### End point description:

Blood samples were collected to measure serum creatinine at the indicated timepoints to assess graft function in DCD renal transplant recipients treated with GSK1070806. Baseline value was the latest pre-dose assessment value. Change from Baseline was post Baseline value minus Baseline value. Only those

participants with data available at the specified time points were analyzed (represented by n=X in the category titles). 99999 indicates data is not available as standard deviation could not be calculated due to n=1. The AP Population is defined as participants having Baseline and at least one post-Baseline assessment.

|                              |           |
|------------------------------|-----------|
| End point type               | Secondary |
| End point timeframe:         |           |
| Baseline and up to 12 months |           |

| End point values                     | GSK1070806 3<br>mg/kg IV |  |  |  |
|--------------------------------------|--------------------------|--|--|--|
| Subject group type                   | Reporting group          |  |  |  |
| Number of subjects analysed          | 7 <sup>[3]</sup>         |  |  |  |
| Units: Micromoles per liter          |                          |  |  |  |
| arithmetic mean (standard deviation) |                          |  |  |  |
| Screening, n=7                       | 679.0 (± 175.14)         |  |  |  |
| Day 0, n=7                           | -39.3 (± 160.09)         |  |  |  |
| Day 1, n=7                           | -44.7 (± 214.06)         |  |  |  |
| Day 2, n=7                           | -99.0 (± 304.29)         |  |  |  |
| Day 3, n=7                           | -36.7 (± 378.28)         |  |  |  |
| Day 4, n=7                           | -104.6 (± 378.79)        |  |  |  |
| Day 5, n=6                           | -57.2 (± 334.19)         |  |  |  |
| Day 6, n=6                           | -75.7 (± 308.22)         |  |  |  |
| Day 7, n=6                           | -43.5 (± 321.91)         |  |  |  |
| Day 8, n=5                           | -150.8 (± 293.48)        |  |  |  |
| Day 9, n=3                           | -24.0 (± 297.82)         |  |  |  |
| Day 10, n=3                          | -53.0 (± 395.94)         |  |  |  |
| Day 11, n=3                          | -97.0 (± 462.46)         |  |  |  |
| Day 12, n=2                          | 110.0 (± 257.39)         |  |  |  |
| Day 13, n=2                          | 38.0 (± 209.30)          |  |  |  |
| Day 14, n=2                          | 4.0 (± 190.92)           |  |  |  |
| Day 15, n=2                          | -51.0 (± 172.53)         |  |  |  |
| Day 16, n=2                          | -61.5 (± 173.24)         |  |  |  |
| Day 17, n=2                          | -107.5 (± 143.54)        |  |  |  |
| Day 18, n=2                          | -145.0 (± 123.04)        |  |  |  |
| Day 19, n=2                          | -173.5 (± 95.46)         |  |  |  |
| Day 20, n=2                          | -183.5 (± 81.32)         |  |  |  |

|                |                   |  |  |  |
|----------------|-------------------|--|--|--|
| Day 21, n=1    | -117.0 (± 99999)  |  |  |  |
| Day 22, n=1    | -91.0 (± 99999)   |  |  |  |
| Day 23, n=1    | -95.0 (± 99999)   |  |  |  |
| Day 24, n=1    | -115.0 (± 99999)  |  |  |  |
| Day 25, n=1    | -152.0 (± 99999)  |  |  |  |
| Day 26, n=1    | -155.0 (± 99999)  |  |  |  |
| Day 27, n=1    | -175.0 (± 99999)  |  |  |  |
| Day 28, n=1    | -191.0 (± 99999)  |  |  |  |
| Day 30, n=7    | -478.3 (± 225.47) |  |  |  |
| Day 90, n=7    | -489.9 (± 214.06) |  |  |  |
| 6 months, n=7  | -467.4 (± 232.49) |  |  |  |
| 12 months, n=6 | -490.5 (± 224.32) |  |  |  |

Notes:

[3] - AP Population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Urine volume at Baseline and change from Baseline over time post transplant

|                 |                                                                             |
|-----------------|-----------------------------------------------------------------------------|
| End point title | Urine volume at Baseline and change from Baseline over time post transplant |
|-----------------|-----------------------------------------------------------------------------|

End point description:

Urine volume at Baseline and over time post transplant was measured to assess graft function in DCD renal transplant recipients treated with GSK1070806. Baseline value was the latest pre-dose assessment value. Change from Baseline was post Baseline value minus Baseline value. All Subjects Population comprised of participants who received the dose of study medication. 99999 indicates data is not available as standard deviation could not be calculated due to n=1. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline (Pre-operative) and up to Day 28

|                                      |                       |  |  |  |
|--------------------------------------|-----------------------|--|--|--|
| <b>End point values</b>              | GSK1070806 3 mg/kg IV |  |  |  |
| Subject group type                   | Reporting group       |  |  |  |
| Number of subjects analysed          | 7 <sup>[4]</sup>      |  |  |  |
| Units: Liter                         |                       |  |  |  |
| arithmetic mean (standard deviation) |                       |  |  |  |
| Day 0, n=4                           | -0.5150 (± 0.59533)   |  |  |  |

|                    |                         |  |  |  |
|--------------------|-------------------------|--|--|--|
| Day 1, n=5         | 0.5862 ( $\pm$ 1.56917) |  |  |  |
| Day 2, n=5         | 1.2820 ( $\pm$ 2.62989) |  |  |  |
| Day 3, n=5         | 0.8840 ( $\pm$ 1.04040) |  |  |  |
| Day 4, n=5         | 1.1480 ( $\pm$ 1.00442) |  |  |  |
| Day 5, n=4         | 0.8270 ( $\pm$ 1.02297) |  |  |  |
| Day 6, n=4         | 1.1168 ( $\pm$ 1.30252) |  |  |  |
| Day 7, n=4         | 1.2985 ( $\pm$ 1.37212) |  |  |  |
| Day 8, n=3         | 1.2090 ( $\pm$ 1.20354) |  |  |  |
| Day 9, n=2         | 1.2135 ( $\pm$ 1.46866) |  |  |  |
| Day 10, n=2        | 0.8585 ( $\pm$ 0.62720) |  |  |  |
| Day 11, n=2        | 0.4985 ( $\pm$ 0.22840) |  |  |  |
| Day 12, n=1        | 1.4000 ( $\pm$ 99999)   |  |  |  |
| Day 13, n=1        | 1.6900 ( $\pm$ 99999)   |  |  |  |
| Day 14, n=1        | 1.1800 ( $\pm$ 99999)   |  |  |  |
| Day 15, n=1        | 1.5500 ( $\pm$ 99999)   |  |  |  |
| Day 16, n=1        | 1.8500 ( $\pm$ 99999)   |  |  |  |
| Day 17, n=1        | 1.5000 ( $\pm$ 99999)   |  |  |  |
| Day 18, n=1        | 1.9000 ( $\pm$ 99999)   |  |  |  |
| Day 19, n=1        | 1.6000 ( $\pm$ 99999)   |  |  |  |
| Day 20, n=1        | 1.2500 ( $\pm$ 99999)   |  |  |  |
| Day 21, n=1        | 0.7500 ( $\pm$ 99999)   |  |  |  |
| Day 22, n=1        | 1.0500 ( $\pm$ 99999)   |  |  |  |
| Day 23, n=1        | 1.1500 ( $\pm$ 99999)   |  |  |  |
| Day 24, n=1        | 1.4500 ( $\pm$ 99999)   |  |  |  |
| Day 25, n=1        | 2.0500 ( $\pm$ 99999)   |  |  |  |
| Day 26, n=1        | 2.0000 ( $\pm$ 99999)   |  |  |  |
| Day 27, n=1        | 1.5500 ( $\pm$ 99999)   |  |  |  |
| Day 28, n=1        | 1.4600 ( $\pm$ 99999)   |  |  |  |
| Pre-operative, n=5 | 0.6700 ( $\pm$ 0.60581) |  |  |  |

Notes:

[4] - All Subjects Population

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of participants in the first 7 days with: primary non function, functional DGF, intermediate graft function, immediate graft function

|                 |                                                                                                                                              |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Number of participants in the first 7 days with: primary non function, functional DGF, intermediate graft function, immediate graft function |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

Number of participants in the first 7 days with primary non function, functional DGF, intermediate graft function and immediate graft function were evaluated to access graft function in DCD renal transplant recipients treated with GSK1070806.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to Day 7

|                                   |                       |  |  |  |
|-----------------------------------|-----------------------|--|--|--|
| <b>End point values</b>           | GSK1070806 3 mg/kg IV |  |  |  |
| Subject group type                | Reporting group       |  |  |  |
| Number of subjects analysed       | 7 <sup>[5]</sup>      |  |  |  |
| Units: Participants               |                       |  |  |  |
| Primary Non Function              | 1                     |  |  |  |
| 3 day Functional DGF              | 3                     |  |  |  |
| 7 day Functional DGF              | 5                     |  |  |  |
| 3 day Intermediate Graft Function | 0                     |  |  |  |
| 7 day Intermediate Graft Function | 1                     |  |  |  |
| 3 day Immediate Graft Function    | 1                     |  |  |  |
| 7 day Immediate Graft Function    | 0                     |  |  |  |

Notes:

[5] - All Subjects Population

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of participants with episodes of biopsy-proven acute rejection

|                 |                                                                       |
|-----------------|-----------------------------------------------------------------------|
| End point title | Number of participants with episodes of biopsy-proven acute rejection |
|-----------------|-----------------------------------------------------------------------|

End point description:

Number of participants with episodes of biopsy-proven acute rejection were evaluated to assess the effect of GSK1070806 on acute rejection risk, and rejection/ Pharmacodynamics (PD) biomarkers. Only those participants with data available at the specified time points were analyzed.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to 12 months

|                             |                       |  |  |  |
|-----------------------------|-----------------------|--|--|--|
| <b>End point values</b>     | GSK1070806 3 mg/kg IV |  |  |  |
| Subject group type          | Reporting group       |  |  |  |
| Number of subjects analysed | 2 <sup>[6]</sup>      |  |  |  |
| Units: Participants         | 1                     |  |  |  |

Notes:

[6] - AP Population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Serum Interferon gamma-induced Protein 10 (IP-10) and Serum Monokine Induced Gamma interferon (Mig) levels at Baseline and Change from Baseline over time post transplant

|                 |                                                                                                                                                                           |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Serum Interferon gamma-induced Protein 10 (IP-10) and Serum Monokine Induced Gamma interferon (Mig) levels at Baseline and Change from Baseline over time post transplant |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

The interferon-gamma -inducible chemokine IP10 and the interferon-gamma -inducible chemokine Mig have been identified as an early predictive marker of antibody-mediated kidney graft rejection. Baseline value was the latest pre-dose assessment value. Change from Baseline was calculated as post Baseline value minus Baseline value. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline and at 0.75 hours, 4-8 hours, Day 1, Day 2, Day 30, Day 90, 6 months and 12 months post reperfusion

|                                      |                           |  |  |  |
|--------------------------------------|---------------------------|--|--|--|
| <b>End point values</b>              | GSK1070806 3 mg/kg IV     |  |  |  |
| Subject group type                   | Reporting group           |  |  |  |
| Number of subjects analysed          | 7 <sup>[7]</sup>          |  |  |  |
| Units: Picograms per Liter           |                           |  |  |  |
| arithmetic mean (standard deviation) |                           |  |  |  |
| IP-10, Baseline, n=7                 | 518.83817 (± 269.010355)  |  |  |  |
| IP-10, Day 0, 0.75 hour, n=6         | -48.36607 (± 178.371827)  |  |  |  |
| IP-10, Day 0, 4-8 hour, n=6          | -262.30099 (± 176.415675) |  |  |  |
| IP-10, Day 1, n=6                    | -214.27224 (± 198.587957) |  |  |  |
| IP-10, Day 2, n=5                    | -91.07498 (± 397.795706)  |  |  |  |
| IP-10, Day 30, n=6                   | -215.96831 (± 350.419207) |  |  |  |
| IP-10, Day 90, n=7                   | 221.97286 (± 617.906913)  |  |  |  |
| IP-10, 6 months, n=7                 | 145.05039 (± 846.080946)  |  |  |  |
| IP-10, 12 months, n=5                | 241.29317 (± 564.374462)  |  |  |  |
| Mig, Baseline, n=7                   | 175.76865 (± 194.372235)  |  |  |  |

|                            |                           |  |  |  |
|----------------------------|---------------------------|--|--|--|
| Mig, Day 0, 0.75 hour, n=6 | -14.02145 (± 32.535124)   |  |  |  |
| Mig, Day 0, 4-8 hour, n=6  | -49.28436 (± 54.067623)   |  |  |  |
| Mig, Day 1, n=6            | -67.61716 (± 61.009544)   |  |  |  |
| Mig, Day 2, n=5            | -133.99600 (± 165.972042) |  |  |  |
| Mig, Day 30, n=6           | -159.17646 (± 207.921389) |  |  |  |
| Mig, Day 90, n=7           | -78.69081 (± 227.901113)  |  |  |  |
| Mig, 6 months, n=7         | -43.68148 (± 325.518838)  |  |  |  |
| Mig, 12 months, n=5        | -30.52711 (± 75.218188)   |  |  |  |

Notes:

[7] - All Subjects Population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of participants with dialysis events in the first 30 days post-transplant

|                 |                                                                                  |
|-----------------|----------------------------------------------------------------------------------|
| End point title | Number of participants with dialysis events in the first 30 days post-transplant |
|-----------------|----------------------------------------------------------------------------------|

End point description:

Number of participants with dialysis events in the first 30 days post transplant was evaluated to assess the effect of GSK1070806 on dialysis dependency and graft survival. The AP Population is defined as participants having Baseline and at least one post-Baseline assessment.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to 30 days

|                             |                       |  |  |  |
|-----------------------------|-----------------------|--|--|--|
| <b>End point values</b>     | GSK1070806 3 mg/kg IV |  |  |  |
| Subject group type          | Reporting group       |  |  |  |
| Number of subjects analysed | 7 <sup>[8]</sup>      |  |  |  |
| Units: Participants         |                       |  |  |  |
| Participants                | 5                     |  |  |  |

Notes:

[8] - AP Population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of participants who are dialysis independent at visits up to 12 months post-transplant

|                 |                                                                                               |
|-----------------|-----------------------------------------------------------------------------------------------|
| End point title | Number of participants who are dialysis independent at visits up to 12 months post-transplant |
|-----------------|-----------------------------------------------------------------------------------------------|

End point description:

Number of participants who are dialysis independent at visits up to 12 months post transplant was evaluated to assess the effect of GSK1070806 on dialysis dependency and graft survival.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to 12 months

|                             |                       |  |  |  |
|-----------------------------|-----------------------|--|--|--|
| <b>End point values</b>     | GSK1070806 3 mg/kg IV |  |  |  |
| Subject group type          | Reporting group       |  |  |  |
| Number of subjects analysed | 7 <sup>[9]</sup>      |  |  |  |
| Units: Participants         | 2                     |  |  |  |

Notes:

[9] - All Subjects Population

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of participants with adverse event (AE) and serious adverse event (SAE)

|                 |                                                                                |
|-----------------|--------------------------------------------------------------------------------|
| End point title | Number of participants with adverse event (AE) and serious adverse event (SAE) |
|-----------------|--------------------------------------------------------------------------------|

End point description:

AE is any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect or any other situation according to medical or scientific judgment were categorized as SAE.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to 12 months

|                             |                       |  |  |  |
|-----------------------------|-----------------------|--|--|--|
| <b>End point values</b>     | GSK1070806 3 mg/kg IV |  |  |  |
| Subject group type          | Reporting group       |  |  |  |
| Number of subjects analysed | 7 <sup>[10]</sup>     |  |  |  |
| Units: Participants         |                       |  |  |  |
| Any AE                      | 7                     |  |  |  |
| Any SAE                     | 6                     |  |  |  |

Notes:

[10] - AP Population

### Statistical analyses

No statistical analyses for this end point

**Secondary: Number of participants having any abnormality in hematology results of Potential Clinical Importance**

|                 |                                                                                                      |
|-----------------|------------------------------------------------------------------------------------------------------|
| End point title | Number of participants having any abnormality in hematology results of Potential Clinical Importance |
|-----------------|------------------------------------------------------------------------------------------------------|

## End point description:

Blood samples were collected to evaluate hematology parameters. Number of participants with abnormality in any hematology parameter results of potential clinical importance (high or low) observed at any time post Baseline are presented. PCI (high or low) was considered if hematocrit (high: >0.54; low: change from baseline [CFB] 0.075 decrease), hemoglobin (high: 180; low: CFB 25 decrease), lymphocytes (low: 0.8), neutrophil count (low: 1.5), platelet count (low: 100; high: 550), White blood cells (low: 3; high: 20).

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

## End point timeframe:

Up to 12 months

|                             |                       |  |  |  |
|-----------------------------|-----------------------|--|--|--|
| <b>End point values</b>     | GSK1070806 3 mg/kg IV |  |  |  |
| Subject group type          | Reporting group       |  |  |  |
| Number of subjects analysed | 7 <sup>[11]</sup>     |  |  |  |
| Units: Participants         |                       |  |  |  |
| Lymphocytes, Low            | 7                     |  |  |  |
| Hematocrit, High            | 1                     |  |  |  |
| White Blood Cells, High     | 1                     |  |  |  |
| White Blood Cells, Low      | 1                     |  |  |  |
| Platelet Count, Low         | 1                     |  |  |  |
| Total neutrophils, Low      | 1                     |  |  |  |

## Notes:

[11] - All Subjects Population

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Number of participants having any abnormal clinical chemistry results of Potential Clinical Importance**

|                 |                                                                                                        |
|-----------------|--------------------------------------------------------------------------------------------------------|
| End point title | Number of participants having any abnormal clinical chemistry results of Potential Clinical Importance |
|-----------------|--------------------------------------------------------------------------------------------------------|

## End point description:

Blood samples were collected to evaluate clinical chemistry parameters. Number of participants with abnormal chemistry results of potential clinical importance (high or low) in any of these parameters at any time post Baseline visit have been presented. PCI (high or low) was considered if albumin (low < 30), calcium (low < 2, high > 2.75), creatinine (high: CHB > 44.2 increase), glucose (low < 3, high > 9), magnesium (low < 0.5, high > 1.23), phosphorus (low < 0.8, high > 1.6), potassium (low < 3, high > 5.5), sodium (low: 130, high > 150), Total carbon dioxide (CO<sub>2</sub>) (low: 18, high > 32), Alanine aminotransferase (ALT) (high >= 2\*upper limit of normal [ULN]), Aspartate aminotransferase (AST) (high: >= 2\*ULN), Alkaline phosphatase (ALP) (high: >= 2\*ULN), Total bilirubin (high: > 2\*ULN), Total bilirubin+ALT (high: 1.5\*ULN total bilirubin with >= 2\*ULN ALT).

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

## End point timeframe:

Up to 12 months

|                             |                       |  |  |  |
|-----------------------------|-----------------------|--|--|--|
| <b>End point values</b>     | GSK1070806 3 mg/kg IV |  |  |  |
| Subject group type          | Reporting group       |  |  |  |
| Number of subjects analysed | 7 <sup>[12]</sup>     |  |  |  |
| Units: Participants         |                       |  |  |  |
| Albumin, Low                | 6                     |  |  |  |
| Calcium, Low                | 7                     |  |  |  |
| Glucose, High               | 5                     |  |  |  |
| Potassium, Low              | 1                     |  |  |  |
| Potassium, High             | 3                     |  |  |  |
| Total Bilirubin, High       | 1                     |  |  |  |
| Sodium, Low                 | 2                     |  |  |  |
| ALT, High                   | 1                     |  |  |  |
| ALP, High                   | 1                     |  |  |  |
| AST, High                   | 1                     |  |  |  |

Notes:

[12] - All Subjects Population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of participants having any abnormality of Potential Clinical Importance of vital signs results

|                 |                                                                                                       |
|-----------------|-------------------------------------------------------------------------------------------------------|
| End point title | Number of participants having any abnormality of Potential Clinical Importance of vital signs results |
|-----------------|-------------------------------------------------------------------------------------------------------|

End point description:

Vital signs parameters included analysis of systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR) and body temperature. Number of participants with any abnormality of potential clinical importance (high or low) in any of these vitals signs at any time post Baseline visit have been presented. PCI (high or low) was considered if SBP (low: <85, high:>160), DBP (low: <45, high>100), HR (low: <40, high: >110) and temperature (low: <35.5, high: >37.5).

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to 12 months

|                             |                       |  |  |  |
|-----------------------------|-----------------------|--|--|--|
| <b>End point values</b>     | GSK1070806 3 mg/kg IV |  |  |  |
| Subject group type          | Reporting group       |  |  |  |
| Number of subjects analysed | 7 <sup>[13]</sup>     |  |  |  |
| Units: Participants         |                       |  |  |  |
| SBP, High                   | 5                     |  |  |  |
| SBP, Low                    | 1                     |  |  |  |
| DBP, High                   | 2                     |  |  |  |
| DBP, Low                    | 1                     |  |  |  |
| HR, High                    | 1                     |  |  |  |

|                   |   |  |  |  |
|-------------------|---|--|--|--|
| Temperature, High | 1 |  |  |  |
| Temperature, Low  | 2 |  |  |  |

Notes:

[13] - All Subjects Population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of participants having infections

|                                                                                     |                                          |
|-------------------------------------------------------------------------------------|------------------------------------------|
| End point title                                                                     | Number of participants having infections |
| End point description:<br>Number of participants having infections were summarized. |                                          |
| End point type                                                                      | Secondary                                |
| End point timeframe:<br>Up to 12 months                                             |                                          |

|                             |                       |  |  |  |
|-----------------------------|-----------------------|--|--|--|
| <b>End point values</b>     | GSK1070806 3 mg/kg IV |  |  |  |
| Subject group type          | Reporting group       |  |  |  |
| Number of subjects analysed | 7 <sup>[14]</sup>     |  |  |  |
| Units: Participants         | 5                     |  |  |  |

Notes:

[14] - All Subjects Population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Serum concentrations of GSK1070806

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                    |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Serum concentrations of GSK1070806 |
| End point description:<br>Serial blood samples were collected to evaluate PK of GSK1070806 at Pre-operative, 0.75 hours, 4-8 hours, 24 hours, 168 hours, Day 30, Day 90, 6 months and 12 months after kidney reperfusion. PK Population included participants in the 'All Subjects' Population for whom a serum PK sample is obtained and analyzed for GSK1070806. 99999 indicates data was not available as standard deviation is not calculated as most of the values at these time points were imputed. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles). |                                    |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Secondary                          |
| End point timeframe:<br>Pre-operative, 0.75 hours, 4-8 hours, 24 hours, 168 hours, Day 30, Day 90, 6 months and 12 months after kidney reperfusion                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                    |

|                                      |                       |  |  |  |
|--------------------------------------|-----------------------|--|--|--|
| <b>End point values</b>              | GSK1070806 3 mg/kg IV |  |  |  |
| Subject group type                   | Reporting group       |  |  |  |
| Number of subjects analysed          | 7 <sup>[15]</sup>     |  |  |  |
| Units: Nanograms per milliliter      |                       |  |  |  |
| arithmetic mean (standard deviation) |                       |  |  |  |
| Pre-operative, n=7                   | 0.0 (± 99999)         |  |  |  |
| 0.75 hours, n=6                      | 58783.3 (± 11287.77)  |  |  |  |
| 4-8 hours, n=6                       | 60033.3 (± 13577.43)  |  |  |  |
| 24 hours, n=6                        | 50933.3 (± 12681.11)  |  |  |  |
| 168 hours, n=5                       | 28260.0 (± 9643.29)   |  |  |  |
| Day 30, n=6                          | 17366.7 (± 6809.60)   |  |  |  |
| Day 90, n=7                          | 5047.0 (± 2914.37)    |  |  |  |
| 6 months, n=7                        | 1083.4 (± 720.18)     |  |  |  |
| 12 months, n=6                       | 19.2 (± 99999)        |  |  |  |

Notes:

[15] - PK Population

### Statistical analyses

No statistical analyses for this end point

### Secondary: Maximum plasma concentration (Cmax) of GSK1070806

|                                                                                                                                                                                                                                                                                 |                                                   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                 | Maximum plasma concentration (Cmax) of GSK1070806 |
| End point description:                                                                                                                                                                                                                                                          |                                                   |
| Serial blood samples were collected to evaluate PK of GSK1070806 at Pre-operative, 0.75 hours, 4-8 hours, 24 hours, 168 hours, Day 30, Day 90, 6 months and 12 months after kidney reperfusion. Log-transformed geometric mean and 95% confidence interval have been presented. |                                                   |
| End point type                                                                                                                                                                                                                                                                  | Secondary                                         |
| End point timeframe:                                                                                                                                                                                                                                                            |                                                   |
| Pre-operative, 0.75 hours, 4-8 hours, 24 hours, 168 hours, Day 30, Day 90, 6 months and 12 months after kidney reperfusion                                                                                                                                                      |                                                   |

|                                          |                               |  |  |  |
|------------------------------------------|-------------------------------|--|--|--|
| <b>End point values</b>                  | GSK1070806 3 mg/kg IV         |  |  |  |
| Subject group type                       | Reporting group               |  |  |  |
| Number of subjects analysed              | 7 <sup>[16]</sup>             |  |  |  |
| Units: Log (nanograms per milliliter)    |                               |  |  |  |
| geometric mean (confidence interval 95%) | 36315.1 (10237.6 to 128818.4) |  |  |  |

Notes:

[16] - PK Population

### Statistical analyses

No statistical analyses for this end point

**Secondary: Area under the plasma concentration time curve (AUC) from time 0 to the last measurable concentration (AUC[0-t]) and AUC from time 0 to infinite time (AUC[0-inf]) of GSK1070806**

|                 |                                                                                                                                                                                  |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Area under the plasma concentration time curve (AUC) from time 0 to the last measurable concentration (AUC[0-t]) and AUC from time 0 to infinite time (AUC[0-inf]) of GSK1070806 |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

Blood samples were to be collected to evaluate PK of GSK1070806 at Pre-operative, 0.75 hours, 4-8 hours, 24 hours, 168 hours, Day 30, Day 90, 6 months and 12 months after kidney reperfusion. Log-transformed geometric mean and 95% confidence interval have been presented.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Pre-operative, 0.75 hours, 4-8 hours, 24 hours, 168 hours, Day 30, Day 90, 6 months and 12 months after kidney reperfusion

|                                            |                                          |  |  |  |
|--------------------------------------------|------------------------------------------|--|--|--|
| <b>End point values</b>                    | GSK1070806 3 mg/kg IV                    |  |  |  |
| Subject group type                         | Reporting group                          |  |  |  |
| Number of subjects analysed                | 7 <sup>[17]</sup>                        |  |  |  |
| Units: Log (Hour*nanograms per milliliter) |                                          |  |  |  |
| geometric mean (confidence interval 95%)   |                                          |  |  |  |
| AUC (0-t), n=7                             | 26131338.2<br>(8927844.0 to 76485076.9)  |  |  |  |
| AUC (0-inf), n=6                           | 41032450.7<br>(28127219.0 to 59858815.6) |  |  |  |

Notes:

[17] - PK Population

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Serum levels of free, total, and GSK1070806 bound Interleukin 18 (IL-18) at Baseline and change from Baseline over time post-transplant**

|                 |                                                                                                                                         |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Serum levels of free, total, and GSK1070806 bound Interleukin 18 (IL-18) at Baseline and change from Baseline over time post-transplant |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------|

End point description:

IL-18 is itself rapidly secreted from intracellular stores following inflammasome mediated-activation. The appearance of IL-18 marks the initiation of the inflammatory response leading to further injury. Blood samples were collected at indicated time points to assess serum levels of free, total, and GSK1070806 bound IL-18. Baseline value was the latest pre-dose assessment value. Change from Baseline was post Baseline value minus Baseline value. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles). 99999 indicates data was not available due to n=0.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline and at 0.75 hours, 4-8 hours, Day 1, Day 2, Day 30, Day 90, 6 months and 12 months post

|                                                    |                            |  |  |  |
|----------------------------------------------------|----------------------------|--|--|--|
| <b>End point values</b>                            | GSK1070806 3<br>mg/kg IV   |  |  |  |
| Subject group type                                 | Reporting group            |  |  |  |
| Number of subjects analysed                        | 7 <sup>[18]</sup>          |  |  |  |
| Units: Picograms per milliliter                    |                            |  |  |  |
| arithmetic mean (standard deviation)               |                            |  |  |  |
| Serum Free IL-18, Baseline<br>(preoperative), n=5  | 26.840 (±<br>37.0569)      |  |  |  |
| Serum Free IL-18, Day 0, 0.75 hour,<br>n=5         | -22.620 (±<br>37.1672)     |  |  |  |
| Serum Free IL-18, Day 0, 4-8 hour, n=5             | -22.540 (±<br>34.1535)     |  |  |  |
| Serum Free IL-18, Day 1, n=5                       | -23.890 (±<br>37.0569)     |  |  |  |
| Serum Free IL-18, Day 2, n=4                       | -5.263 (±<br>14.4846)      |  |  |  |
| Serum Free IL-18, Day 30, n=4                      | -27.925 (±<br>41.5019)     |  |  |  |
| Serum Free IL-18, Day 90, n=2                      | -2.250 (±<br>3.1820)       |  |  |  |
| Serum Free IL-18, 6 months, n=0                    | 99999 (±<br>99999)         |  |  |  |
| Serum Free IL-18, 12 months, n=0                   | 99999 (±<br>99999)         |  |  |  |
| Serum Bound IL-18, Baseline<br>(preoperative), n=5 | 21.156 (±<br>7.5139)       |  |  |  |
| Serum Bound IL-18, Day 0, 0.75 hour,<br>n=5        | 362.084 (±<br>220.2164)    |  |  |  |
| Serum Bound IL-18, Day 0, 4-8 hour,<br>n=5         | 314.864 (±<br>139.1919)    |  |  |  |
| Serum Bound IL-18, Day 1, n=5                      | 472.204 (±<br>193.0366)    |  |  |  |
| Serum Bound IL-18, Day 2, n=4                      | 485.740 (±<br>252.2876)    |  |  |  |
| Serum Bound IL-18, Day 30, n=4                     | 617.543 (±<br>282.9679)    |  |  |  |
| Serum Bound IL-18, Day 90, n=2                     | 946.020 (±<br>21.3971)     |  |  |  |
| Serum Bound IL-18, 6 months, n=0                   | 99999 (±<br>99999)         |  |  |  |
| Serum Bound IL-18, 12 months, n=0                  | 99999 (±<br>99999)         |  |  |  |
| Serum Total IL-18, Baseline<br>(preoperative), n=7 | 130.6857 (±<br>71.37029)   |  |  |  |
| Serum Total IL-18, Day 0, 0.75 hour,<br>n=6        | 572.3333 (±<br>368.68620)  |  |  |  |
| Serum Total IL-18, Day 0, 4-8 hour,<br>n=6         | 576.3667 (±<br>273.88543)  |  |  |  |
| Serum Total IL-18, Day 1, n=6                      | 636.5667 (±<br>208.88294)  |  |  |  |
| Serum Total IL-18, Day 2, n=5                      | 660.6600 (±<br>297.32305)  |  |  |  |
| Serum Total IL-18, Day 30, n=6                     | 1175.5000 (±<br>710.48323) |  |  |  |

|                                   |                               |  |  |  |
|-----------------------------------|-------------------------------|--|--|--|
| Serum Total IL-18, Day 90, n=7    | 1423.5429 ( $\pm$ 685.42012)  |  |  |  |
| Serum Total IL-18, 6 months, n=7  | 1303.7143 ( $\pm$ 1006.89585) |  |  |  |
| Serum Total IL-18, 12 months, n=6 | 1091.0833 ( $\pm$ 1102.78861) |  |  |  |

Notes:

[18] - All Subjects Population

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of participants with positive result in anti-GSK1070806 antibodies (ADAs)

|                 |                                                                                  |
|-----------------|----------------------------------------------------------------------------------|
| End point title | Number of participants with positive result in anti-GSK1070806 antibodies (ADAs) |
|-----------------|----------------------------------------------------------------------------------|

End point description:

Serum samples were to be collected to test for the presence of antibodies against GSK1070806 at indicated time points. The presence of anti-GSK1070806 binding antibodies were to be assessed using a validated electrochemiluminescent (ECL) immunoassay. Data was not collected as the immunogenicity samples were not collected for this terminated indication since healthy volunteers showed low titers and Type 2 Diabetics showed no titers per Investigator's Brochure.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

0.75 hour and 4-8 hour on Day 0, Day 1, Day 2, Day 30, Day 90, 6 months and 12 months post reperfusion

|                             |                       |  |  |  |
|-----------------------------|-----------------------|--|--|--|
| <b>End point values</b>     | GSK1070806 3 mg/kg IV |  |  |  |
| Subject group type          | Reporting group       |  |  |  |
| Number of subjects analysed | 0 <sup>[19]</sup>     |  |  |  |
| Units: Participants         |                       |  |  |  |

Notes:

[19] - All Subjects Population

## Statistical analyses

No statistical analyses for this end point

### Secondary: ADA titer before and after GSK1070806 administration

|                 |                                                      |
|-----------------|------------------------------------------------------|
| End point title | ADA titer before and after GSK1070806 administration |
|-----------------|------------------------------------------------------|

End point description:

Serum samples were to be collected to test for the presence of antibodies against GSK1070806 at indicated time points. The presence of ADA titer was to be assessed using a validated ECL immunoassay. Data was not collected as the immunogenicity samples were not collected for this terminated indication since healthy volunteers showed low titers and Type 2 Diabetics showed no titers per Investigator's Brochure.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

0.75 hour and 4-8 hour on Day 0, Day 1, Day 2, Day 30, Day 90, 6 months and 12 months post reperfusion

|                                      |                          |  |  |  |
|--------------------------------------|--------------------------|--|--|--|
| <b>End point values</b>              | GSK1070806 3<br>mg/kg IV |  |  |  |
| Subject group type                   | Reporting group          |  |  |  |
| Number of subjects analysed          | 0 <sup>[20]</sup>        |  |  |  |
| Units: Picograms per milliliter      |                          |  |  |  |
| arithmetic mean (standard deviation) | ( )                      |  |  |  |

Notes:

[20] - All Subjects Population

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

On-treatment serious adverse events (SAEs) and non-serious AEs were defined as events occurring from the first dose until 12 months.

Adverse event reporting additional description:

SAEs and Non-serious AEs were collected for All Subjects Population, comprised of participants who received the dose of study medication.

|                 |            |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

### Dictionary used

|                 |        |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

|                    |     |
|--------------------|-----|
| Dictionary version | 2.0 |
|--------------------|-----|

### Reporting groups

|                       |                       |
|-----------------------|-----------------------|
| Reporting group title | GSK1070806 3 mg/kg IV |
|-----------------------|-----------------------|

Reporting group description:

Participants received a single dose of 3 milligram per kilogram (mg/kg) intravenous (IV) infusion of GSK1070806 administered prior to kidney allograft reperfusion. Participants also received a combination immunosuppression comprised of basiliximab; mycophenolate mofetil (MMF) or aziothioprine; tacrolimus; and corticosteroids based on the clinical judgment of the investigator.

| Serious adverse events                            | GSK1070806 3 mg/kg IV |  |  |
|---------------------------------------------------|-----------------------|--|--|
| Total subjects affected by serious adverse events |                       |  |  |
| subjects affected / exposed                       | 6 / 7 (85.71%)        |  |  |
| number of deaths (all causes)                     | 0                     |  |  |
| number of deaths resulting from adverse events    | 0                     |  |  |
| Injury, poisoning and procedural complications    |                       |  |  |
| Transplant dysfunction                            |                       |  |  |
| subjects affected / exposed                       | 1 / 7 (14.29%)        |  |  |
| occurrences causally related to treatment / all   | 0 / 1                 |  |  |
| deaths causally related to treatment / all        | 0 / 0                 |  |  |
| Cardiac disorders                                 |                       |  |  |
| Ventricular fibrillation                          |                       |  |  |
| subjects affected / exposed                       | 1 / 7 (14.29%)        |  |  |
| occurrences causally related to treatment / all   | 0 / 2                 |  |  |
| deaths causally related to treatment / all        | 0 / 0                 |  |  |
| Cardiac failure                                   |                       |  |  |
| subjects affected / exposed                       | 1 / 7 (14.29%)        |  |  |
| occurrences causally related to treatment / all   | 0 / 1                 |  |  |
| deaths causally related to treatment / all        | 0 / 0                 |  |  |

|                                                                                                                                                                                                       |                                          |  |  |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------|--|--|
| Surgical and medical procedures<br>Ureteral stent removal<br>subjects affected / exposed<br>occurrences causally related to treatment / all<br>deaths causally related to treatment / all             | <br><br>1 / 7 (14.29%)<br>0 / 1<br>0 / 0 |  |  |
| General disorders and administration site conditions<br>Hernia<br>subjects affected / exposed<br>occurrences causally related to treatment / all<br>deaths causally related to treatment / all        | <br><br>1 / 7 (14.29%)<br>0 / 1<br>0 / 0 |  |  |
| Immune system disorders<br>Kidney transplant rejection<br>subjects affected / exposed<br>occurrences causally related to treatment / all<br>deaths causally related to treatment / all                | <br><br>1 / 7 (14.29%)<br>0 / 1<br>0 / 0 |  |  |
| Reproductive system and breast disorders<br>Prostatomegaly<br>subjects affected / exposed<br>occurrences causally related to treatment / all<br>deaths causally related to treatment / all            | <br><br>1 / 7 (14.29%)<br>0 / 1<br>0 / 0 |  |  |
| Gastrointestinal disorders<br>Small intestinal obstruction<br>subjects affected / exposed<br>occurrences causally related to treatment / all<br>deaths causally related to treatment / all            | <br><br>1 / 7 (14.29%)<br>0 / 1<br>0 / 0 |  |  |
| Respiratory, thoracic and mediastinal disorders<br>Respiratory arrest<br>subjects affected / exposed<br>occurrences causally related to treatment / all<br>deaths causally related to treatment / all | <br><br>1 / 7 (14.29%)<br>1 / 1<br>0 / 0 |  |  |
| Renal and urinary disorders<br>Ureteric obstruction<br>subjects affected / exposed<br>occurrences causally related to treatment / all<br>deaths causally related to treatment / all                   | <br><br>1 / 7 (14.29%)<br>0 / 1<br>0 / 0 |  |  |

|                                                                                                                                                                          |                                  |  |  |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|--|--|
| End stage renal disease<br>subjects affected / exposed<br>occurrences causally related to treatment / all<br>deaths causally related to treatment / all                  | 1 / 7 (14.29%)<br>0 / 1<br>0 / 0 |  |  |
| Infections and infestations<br>Pneumonia<br>subjects affected / exposed<br>occurrences causally related to treatment / all<br>deaths causally related to treatment / all | 1 / 7 (14.29%)<br>1 / 1<br>0 / 0 |  |  |
| Urinary tract infection<br>subjects affected / exposed<br>occurrences causally related to treatment / all<br>deaths causally related to treatment / all                  | 1 / 7 (14.29%)<br>0 / 3<br>0 / 0 |  |  |
| Visceral leishmaniasis<br>subjects affected / exposed<br>occurrences causally related to treatment / all<br>deaths causally related to treatment / all                   | 1 / 7 (14.29%)<br>0 / 1<br>0 / 0 |  |  |

Frequency threshold for reporting non-serious adverse events: 0 %

|                                                                                                                                       |                          |  |  |
|---------------------------------------------------------------------------------------------------------------------------------------|--------------------------|--|--|
| <b>Non-serious adverse events</b>                                                                                                     | GSK1070806 3<br>mg/kg IV |  |  |
| Total subjects affected by non-serious adverse events<br>subjects affected / exposed                                                  | 7 / 7 (100.00%)          |  |  |
| Vascular disorders<br>Hypertension<br>subjects affected / exposed<br>occurrences (all)                                                | 2 / 7 (28.57%)<br>2      |  |  |
| General disorders and administration site conditions<br>Catheter site haemorrhage<br>subjects affected / exposed<br>occurrences (all) | 1 / 7 (14.29%)<br>1      |  |  |
| Immune system disorders<br>Kidney transplant rejection<br>subjects affected / exposed<br>occurrences (all)                            | 1 / 7 (14.29%)<br>1      |  |  |

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                       |  |  |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|--|
| Transplant rejection<br>subjects affected / exposed<br>occurrences (all)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 1 / 7 (14.29%)<br>1                                                                                                                                                                   |  |  |
| Respiratory, thoracic and mediastinal disorders<br>Epistaxis<br>subjects affected / exposed<br>occurrences (all)<br><br>Wheezing<br>subjects affected / exposed<br>occurrences (all)                                                                                                                                                                                                                                                                                                                                                                                                                                          | 1 / 7 (14.29%)<br>1<br><br>1 / 7 (14.29%)<br>1                                                                                                                                        |  |  |
| Product issues<br>Product contamination<br>subjects affected / exposed<br>occurrences (all)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 1 / 7 (14.29%)<br>1                                                                                                                                                                   |  |  |
| Investigations<br>Blood creatine increased<br>subjects affected / exposed<br>occurrences (all)<br><br>Blood potassium decreased<br>subjects affected / exposed<br>occurrences (all)<br><br>Blood sodium decreased<br>subjects affected / exposed<br>occurrences (all)<br><br>Candida test positive<br>subjects affected / exposed<br>occurrences (all)<br><br>Haemoglobin increased<br>subjects affected / exposed<br>occurrences (all)<br><br>Body temperature decreased<br>subjects affected / exposed<br>occurrences (all)<br><br>Blood alkaline phosphatase increased<br>subjects affected / exposed<br>occurrences (all) | 1 / 7 (14.29%)<br>1<br><br>1 / 7 (14.29%)<br>1<br><br>1 / 7 (14.29%)<br>1<br><br>1 / 7 (14.29%)<br>1<br><br>1 / 7 (14.29%)<br>1<br><br>1 / 7 (14.29%)<br>1<br><br>1 / 7 (14.29%)<br>1 |  |  |

|                                                                                                                          |                     |  |  |
|--------------------------------------------------------------------------------------------------------------------------|---------------------|--|--|
| Blood glucose increased<br>subjects affected / exposed<br>occurrences (all)                                              | 1 / 7 (14.29%)<br>1 |  |  |
| Cytomegalovirus test positive<br>subjects affected / exposed<br>occurrences (all)                                        | 1 / 7 (14.29%)<br>1 |  |  |
| Weight increased<br>subjects affected / exposed<br>occurrences (all)                                                     | 1 / 7 (14.29%)<br>1 |  |  |
| Injury, poisoning and procedural complications<br>Wound evisceration<br>subjects affected / exposed<br>occurrences (all) | 1 / 7 (14.29%)<br>1 |  |  |
| Wound dehiscence<br>subjects affected / exposed<br>occurrences (all)                                                     | 1 / 7 (14.29%)<br>1 |  |  |
| Arteriovenous fistula site complication<br>subjects affected / exposed<br>occurrences (all)                              | 1 / 7 (14.29%)<br>1 |  |  |
| Post procedural discharge<br>subjects affected / exposed<br>occurrences (all)                                            | 1 / 7 (14.29%)<br>1 |  |  |
| Nervous system disorders<br>Tremor<br>subjects affected / exposed<br>occurrences (all)                                   | 1 / 7 (14.29%)<br>1 |  |  |
| Blood and lymphatic system disorders<br>Leukopenia<br>subjects affected / exposed<br>occurrences (all)                   | 1 / 7 (14.29%)<br>1 |  |  |
| Anaemia<br>subjects affected / exposed<br>occurrences (all)                                                              | 5 / 7 (71.43%)<br>5 |  |  |
| Neutropenia<br>subjects affected / exposed<br>occurrences (all)                                                          | 1 / 7 (14.29%)<br>1 |  |  |

|                                                                              |                     |  |  |
|------------------------------------------------------------------------------|---------------------|--|--|
| Thrombocytopenia<br>subjects affected / exposed<br>occurrences (all)         | 2 / 7 (28.57%)<br>2 |  |  |
| Gastrointestinal disorders                                                   |                     |  |  |
| Nausea<br>subjects affected / exposed<br>occurrences (all)                   | 2 / 7 (28.57%)<br>2 |  |  |
| Constipation<br>subjects affected / exposed<br>occurrences (all)             | 4 / 7 (57.14%)<br>4 |  |  |
| Abdominal pain<br>subjects affected / exposed<br>occurrences (all)           | 1 / 7 (14.29%)<br>2 |  |  |
| Diarrhoea<br>subjects affected / exposed<br>occurrences (all)                | 3 / 7 (42.86%)<br>3 |  |  |
| Inguinal hernia<br>subjects affected / exposed<br>occurrences (all)          | 1 / 7 (14.29%)<br>1 |  |  |
| Dyspepsia<br>subjects affected / exposed<br>occurrences (all)                | 1 / 7 (14.29%)<br>1 |  |  |
| Frequent bowel movements<br>subjects affected / exposed<br>occurrences (all) | 1 / 7 (14.29%)<br>1 |  |  |
| Lip swelling<br>subjects affected / exposed<br>occurrences (all)             | 1 / 7 (14.29%)<br>1 |  |  |
| Vomiting<br>subjects affected / exposed<br>occurrences (all)                 | 1 / 7 (14.29%)<br>1 |  |  |
| Skin and subcutaneous tissue disorders                                       |                     |  |  |
| Pruritus<br>subjects affected / exposed<br>occurrences (all)                 | 1 / 7 (14.29%)<br>1 |  |  |
| Decubitus ulcer                                                              |                     |  |  |

|                                     |                |  |  |
|-------------------------------------|----------------|--|--|
| subjects affected / exposed         | 1 / 7 (14.29%) |  |  |
| occurrences (all)                   | 1              |  |  |
| Urticaria                           |                |  |  |
| subjects affected / exposed         | 1 / 7 (14.29%) |  |  |
| occurrences (all)                   | 1              |  |  |
| Renal and urinary disorders         |                |  |  |
| Urinary retention                   |                |  |  |
| subjects affected / exposed         | 2 / 7 (28.57%) |  |  |
| occurrences (all)                   | 4              |  |  |
| Renal disorder                      |                |  |  |
| subjects affected / exposed         | 1 / 7 (14.29%) |  |  |
| occurrences (all)                   | 1              |  |  |
| Ureteric stenosis                   |                |  |  |
| subjects affected / exposed         | 1 / 7 (14.29%) |  |  |
| occurrences (all)                   | 1              |  |  |
| Renal impairment                    |                |  |  |
| subjects affected / exposed         | 1 / 7 (14.29%) |  |  |
| occurrences (all)                   | 1              |  |  |
| Infections and infestations         |                |  |  |
| Urinary tract infection             |                |  |  |
| subjects affected / exposed         | 2 / 7 (28.57%) |  |  |
| occurrences (all)                   | 4              |  |  |
| Escherichia urinary tract infection |                |  |  |
| subjects affected / exposed         | 1 / 7 (14.29%) |  |  |
| occurrences (all)                   | 1              |  |  |
| Influenza                           |                |  |  |
| subjects affected / exposed         | 1 / 7 (14.29%) |  |  |
| occurrences (all)                   | 1              |  |  |
| Lower respiratory tract infection   |                |  |  |
| subjects affected / exposed         | 1 / 7 (14.29%) |  |  |
| occurrences (all)                   | 2              |  |  |
| Postoperative wound infection       |                |  |  |
| subjects affected / exposed         | 1 / 7 (14.29%) |  |  |
| occurrences (all)                   | 1              |  |  |
| Pyelonephritis acute                |                |  |  |

|                                      |                |  |  |
|--------------------------------------|----------------|--|--|
| subjects affected / exposed          | 1 / 7 (14.29%) |  |  |
| occurrences (all)                    | 1              |  |  |
| Bacterial disease carrier            |                |  |  |
| subjects affected / exposed          | 1 / 7 (14.29%) |  |  |
| occurrences (all)                    | 1              |  |  |
| Nail infection                       |                |  |  |
| subjects affected / exposed          | 1 / 7 (14.29%) |  |  |
| occurrences (all)                    | 1              |  |  |
| Pharyngotonsillitis                  |                |  |  |
| subjects affected / exposed          | 1 / 7 (14.29%) |  |  |
| occurrences (all)                    | 1              |  |  |
| Purulent discharge                   |                |  |  |
| subjects affected / exposed          | 1 / 7 (14.29%) |  |  |
| occurrences (all)                    | 1              |  |  |
| Urinary tract infection enterococcal |                |  |  |
| subjects affected / exposed          | 1 / 7 (14.29%) |  |  |
| occurrences (all)                    | 1              |  |  |
| Metabolism and nutrition disorders   |                |  |  |
| Diabetes mellitus                    |                |  |  |
| subjects affected / exposed          | 1 / 7 (14.29%) |  |  |
| occurrences (all)                    | 1              |  |  |
| Acidosis                             |                |  |  |
| subjects affected / exposed          | 1 / 7 (14.29%) |  |  |
| occurrences (all)                    | 2              |  |  |
| Fluid overload                       |                |  |  |
| subjects affected / exposed          | 1 / 7 (14.29%) |  |  |
| occurrences (all)                    | 1              |  |  |
| Hyperkalaemia                        |                |  |  |
| subjects affected / exposed          | 1 / 7 (14.29%) |  |  |
| occurrences (all)                    | 1              |  |  |
| Hypoalbuminaemia                     |                |  |  |
| subjects affected / exposed          | 1 / 7 (14.29%) |  |  |
| occurrences (all)                    | 2              |  |  |
| Hypomagnesaemia                      |                |  |  |
| subjects affected / exposed          | 1 / 7 (14.29%) |  |  |
| occurrences (all)                    | 1              |  |  |

|                             |                |  |  |
|-----------------------------|----------------|--|--|
| Hypoglycaemia               |                |  |  |
| subjects affected / exposed | 1 / 7 (14.29%) |  |  |
| occurrences (all)           | 1              |  |  |
| Hypophosphataemia           |                |  |  |
| subjects affected / exposed | 1 / 7 (14.29%) |  |  |
| occurrences (all)           | 1              |  |  |

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date             | Amendment                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 03 February 2016 | Amendment 01: Updates to clarify select safety criteria; completion of abbreviations table.                                                                                                                                                                                                                                                                                                                                                 |
| 09 August 2016   | Amendment 02: Eligibility Criteria: Allowance of second kidney transplant recipients for enrollment, removal of upper age limits, addition of definition for 'surgical damage' related to transplant organ retrieval; and clarifications to interim analysis and DCD categorization type.                                                                                                                                                   |
| 22 March 2017    | Amendment 03: Dose escalation: clarifications based on data from patients receiving 3 mg/kg dose to escalate to higher dose.                                                                                                                                                                                                                                                                                                                |
| 04 May 2017      | Amendment 04: Eligibility Criteria: Additional exclusion criteria have been added to reduce the chance of enrolling participants with high cardiac risk profiles. Dose escalation: Based on emergent efficacy and pharmacokinetic-pharmacodynamics (PKPD) data, the number of participants required to be treated prior to a decision to escalate dose has been reduced, and stopping criteria following dose escalation have been amended. |

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported